

**REMARKS**


**Rejection Under 35 U.S.C. § 112, First Paragraph, Enablement**

Claims 66-69 and 72-80 were rejected for allegedly lacking enablement. The Examiner concedes that the claims are enabled for insulin, nerve growth factor (NGF), NGF receptor, epidermal growth factor (EGF) receptor, neu, inhibin a, inhibin b, wnt-2 and hepatocyte growth factor (HGF) receptor (c-met). The Examiner argues that the claims are not enabled for Mullerian inhibitory substance, tumor necrosis factor (TNF) receptor type 1 and TNF receptor type 2. Although Applicants maintain that the claims are enabled for these species, the claims have been amended to delete reference to Mullerian inhibitory substance, tumor necrosis factor (TNF) receptor type 1 and TNF receptor type 2, in order to facilitate prosecution of the present application. Applicants reserve all rights to file one or more continuation or divisional applications to canceled subject matter. Applicants respectfully request withdrawal of this rejection and allowance of the claims.

It is believed that no fee is due. However, please apply any charges or credits to deposit account 06-1050.

Respectfully submitted,

Date: June 8, 2007

  
Tina Williams McKeon  
Reg. No. 43,791

Fish & Richardson P.C.  
1180 Peachtree Street, N.E.  
21st Floor  
Atlanta, GA 30309  
Telephone: (404) 892-5005  
Facsimile: (404) 892-5002